Clinical trial
Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension
NCT01960946 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- October 31, 2013
- Completion date
- August 30, 2018
- Enrollment
- 59 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.